2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 863

Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology
Abstract Number: 49

G Protein-Coupled Receptor Kinase 3 Modulates Mesenchymal Stem Cell Proliferation and Differentiation through Sphingosine-1-Phosphate Receptor Regulation
Abstract Number: 2716

Gastrointestinal Involvement in Adult IgA Vasculitis (Henoch–Schönlein purpura): Initial Manifestations and Outcomes
Abstract Number: 2350

Gastrointestinal Microbiota in New-Onset Juvenile Idiopathic Arthritis
Abstract Number: 1505

Gender Bias in the Inheritance of Ankylosing Spondylitis
Abstract Number: 2499

Gender Differences in Axial and Peripheral Spondyloarthritis: Results from the Esperanza Cohort
Abstract Number: 2818

Gene Expression Analysis Demonstrates That Multiple Type 1 Interferons Are Involved in Lupus Pathogenesis
Abstract Number: 1026

Gene Expression Analysis Reveals Common Pathways of Tissue Pathogenesis in Lupus Organ Involvement
Abstract Number: 647

Gene Expression in Cellular Subsets in Psoriatic Disease
Abstract Number: 2764

Gene Expression Profile in Monocytes of Antiphospholipid Syndrome Patients Reveals Novel Altered Genes and Pathways Involved in the Pathophysiology of the Disease
Abstract Number: 2851

General and Abdominal Obesity As Risk Factors for Late-Life Mobility Limitation Among Women with Total Knee or Hip Replacement for Osteoarthritis
Abstract Number: 835

Generation of an Efficient CRISPR-Cas9 Editing Technique in Human Primary B Cells for the Targeted Study of Autoimmune Susceptibility Genes
Abstract Number: 182

Genetic Determinants of Fatigue in Primary Sjögren`s Syndrome – a Genome Wide Association Study
Abstract Number: 1894

Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study
Abstract Number: 532

Genetic Predictors of Iguratimod Clinical Response and Toxicity in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].